### Faculty

#### COURSE DIRECTORS

- **Hagen F. Kennecke, MD, MHA, FRCPC**  
  Medical Director, Cancer Institute  
  Virginia Mason, Seattle, Wash.

- **Michael C. Larsen, MD**  
  Gastroenterologist  
  Digestive Disease Institute at Virginia Mason, Seattle, Wash.

- **Ravi Moonka, MD, FACS**  
  Colorectal Surgeon  
  Digestive Disease Institute at Virginia Mason, Seattle, Wash.

#### KEYNOTE SPEAKER

- **Nancy E. Kemeny, MD**  
  Oncologist  
  Memorial Sloan Kettering Cancer Center, New York City, NY

#### GUEST FACULTY

- **Joseph Carmichael, MD, FASCRS**  
  Surgeon  
  University of California, Irvine

- **Sharlene Gill, MD, MPH, MBA, FRCPC**  
  Professor of Medicine  
  BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada

- **Skye Mayo, MD, MPH**  
  Surgical Oncologist  
  Oregon Health and Science University, Portland, OR

- **Deborah Italiano, BSN, RN, OCN**  
  Professor of Medicine  
  BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada

- **Shayan Irani, MD**  
  Gastroenterologist  
  Associate Director, Pancreatic Center of Excellence

- **Vicky Jones, MD**  
  Oncologist, North Star Lodge Cancer Center

- **Bruce Lin, MD**  
  Hematologist-Oncologist

- **Otto Lin, MD**  
  Gastroenterologist  
  Director, Quality Improvement

- **Patrick C. Marcin, MD**  
  Radiologist

- **Fran J. O’Donnell, BSN, RN, CWCN**  
  Acute Care, Ambulatory Surgery  
  Wound Care Center

- **Huong Pham, MD**  
  Radiation Oncologist

- **Flavio G. Rocha, MD, FACS**  
  HPB Surgical Oncologist  
  Director of Research, Digestive Disease Institute  
  Associate Medical Director, Cancer Institute

- **Vlad V. Simianu, MD, MPH**  
  Colorectal Surgeon

- **Neil Wiegand, PA-C, MCHS**  
  Physician Assistant, General and Colorectal Surgery
Colorctal cancer is the #2 cause of cancer death in North America. While we successfully screen for colorectal cancer, many gaps in evidence-based treatment remain. Current practitioners have questions about the role of circulating tumor DNA in the diagnosis and management of early to advanced colorectal cancer; the role of endoscopic microsurgery in the management of colon cancer; and when full oncologic surgery is required to deliver the most appropriate care for colon cancer. For patients with advanced, unresectable disease, how can hepatic intra-arterial (HIA) chemotherapy allow surgical resection of previously unresectable liver metastasis? What are the latest evidence and guidelines for diagnosis and treatment of colorectal cancer? Join our renowned, multidisciplinary faculty for this stimulating day of learning.

Teaching methods include lecture, question and answer with faculty, panel discussion and case presentation.

TARGET AUDIENCE: This symposium is designed for all healthcare professionals interested in the screening, evaluation, and management of patients with or at risk for colorectal cancer, including MDs, advanced practitioners, and nurses in oncology, surgery, gastroenterology, and primary care, and administrators of those service lines.

OBJECTIVES: At the conclusion of this activity, participants should be able to:

- Discuss how hepatic arterial infusional (HIA) therapy works
- Review current systemic therapy options for the treatment of advanced colorectal cancer
- Summarize consensus recommendations for liver-limited metastatic colorectal cancer
- Describe the HIA Program Development experience at an academic medical center
- Review novel approaches to hepatic arterial therapy
- List requirements for intrahepatic chemotherapy
- Discuss management of unresectable metastatic colorectal cancer with liver metastases only and of unresectable metastatic colorectal cancer with liver and lung metastases
- Review ACS guidelines for colorectal cancer screening and the data behind them
- Describe who is at risk for HPV related dysplasia and squamous cell carcinoma (SCC) of the anus
- Specify the preferred diagnostic and staging for anal cancer
- Select candidates for a watch and wait approach to rectal cancer treatment per NCCN guidelines and current medical literature
- Summarize the current applications and limitations of transanal approaches to cancer
- Describe technical considerations and modalities concerning local excision for rectal cancer
- Differentiate endoscopic from TAMIS/TEMS in the treatment of rectal cancer
- Discuss loco-regional and systemic management of early stage NETS
- Assess the patient perspective of colostomy management
- Compare treatment of Stage I, Stage II, and Stage III Rectal Cancer

Credit Designation: Virginia Mason Medical Center designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of
Agenda

7:00 a.m. Registration opens, breakfast selection available

7:30 a.m. Grand Rounds Presentation: Can We Cure Metastatic Colon Cancer? The Use of Hepatic Arterial Therapy | Nancy Kemeny, MD

8:30 a.m. Break

8:45 a.m. Opening Remarks | Hagen Kennecke, MD

ADVANCED COLORECTAL CANCER

8:50 a.m. Advances in Management of Advanced Colorectal Cancer Sharlene Gill, MD

9:10 a.m. Surgical Management of Liver-Limited Metastatic Colorectal Cancer Flavio Rocha, MD

9:30 a.m. Building an HIA Program: the OHSU Experience | Skye Mayo, MD

9:50 a.m. Locoregional Therapies for Colorectal Liver Metastases | Patrick Marcin, MD

10:10 a.m. Treatment Administration Intrahepatic Chemotherapy Deborah Italiano, RN

10:30 a.m. Panel Discussion: Case Presentations | Moderator: Bruce Lin, MD

10:50 a.m. Break

11:10 a.m. New ACS Guidelines for Colorectal Cancer Screening | Otto Lin, MD

11:30 a.m. Anal Dysplasia and Cancer Screening, Treatment and Prevention Neil Wiegand, PA-C

11:50 a.m. Updates in Management and Surveillance of SCC Anal Cancer Huong Pham, MD

12:10 p.m. Lunch (provided)

SCREENING AND NON-SURGICAL TREATMENT OF DISEASE

1:00 p.m. Management of Rectal Cancer: Trends and Trials Joseph Carmichael, MD

1:20 p.m. Debate: Transanal Minimally Invasive Surgery (TAMIS) and Transanal Endoscopic Microsurgery (TEMS) as Optimal Therapy for Early Rectal Cancer | Vlad Simianu, MD

1:40 p.m. Debate: Total Mesorectal Excision (TME) Remains the Standard First Line Therapy for Early Rectal Cancer | Ravi Moonka, MD

2:00 p.m. Endoscopic Treatments for Early Colorectal Cancer and Advanced Colon Polyps | Shayan Irani, MD

2:20 p.m. Break

2:40 p.m. Colorectal Neuroendocrine Tumors | Hagen Kennecke, MD

3:00 p.m. Colostomy Management and Patient Perspectives | Fran O’Donnell, RN

3:20 p.m. Rectal Cancer Cases | Vicky Jones, MD

3:40 p.m. Closing Remarks, Adjourn

CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Application for CME credit has been filed with the American Academy of Family Physicians (AAFP). Determination of credit is pending.

Virginia Mason is a provider of nursing continuing education contact hours. Provider is approved by the California Board of Registered Nursing, Provider #CEP15905 for 6.25 Contact Hours (6.25 clock hours), March 8, 2019.

Location: The course will be held in Volney Richmond Auditorium on Level One of the Virginia Mason Lindeman Pavilion, 1201 Terry Avenue, Seattle (between Seneca & University Streets.) Please note the Terry Street entrance into Lindeman Pavilion is Level Two. For information, contact the CME Department at 206-341-0142 or email cme@virginiamason.org.
REGISTRATION:
Advances in Colorectal Cancer
Friday, March 8, 2019

Please print clearly

NAME

DEGREE/CREDS

SPECIALTY

ORGANIZATION

ADDRESS

CITY/STATE/ZIP

PHONE

E-MAIL

Please provide one question for the faculty:

☐ I will attend at the Videoconferencing Site in:

For information, call (206) 341-0142.

☐ Please add me to your e-mail list for news of upcoming CME courses at Virginia Mason.

PAYMENT:

Tuition: $195.00

☐ Check enclosed. Make check payable to VMMC – CME

☐ Please charge my: ☐ VISA ☐ MasterCard ☐ American Express ☐ Discover

CARD NUMBER

EXPIRATION DATE

CARDHOLDER NAME

SIGNATURE

Cancellation and Refund Policy: Refunds will be made for a fee of $25 if written notice of cancellation is received at least 14 calendar days prior to the activity.